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OBJECTIVES: Managed care companies implemented step therapy (ST) policies to 
reduce utilization of infused biologics in new patients. The purpose of this 
analysis was to compare market shares for biologic products for plans identified 
with ST policies versus all other claims (Other) in a large US administrative 
database. METHODS: Data from all plans with a ST policy throughout 2010 were 
compared to all other biologic claims during the same time period using data 
from the Wolters Kluwer Prometis® and Medical databases. Available data 
included payer, prescription (Rx), diagnosis (Dx) and procedure (Px) claims with 
unique anonymised patient identifiers. For 2010, biologic claims were evaluated 
based on: patients with Rx data having at least one biologic prescription and 
patients with Rx and Px data, for the subset with ≥ 1 Rx claim (any type) and ≥ 1 
medical claim (all cause). The number and percentage of patients receiving a 
biologic in 2010, was described. A secondary analysis of only subcutaneous (SC) 
products in the Rx database was conducted. RESULTS: Sixteen different plans 
had a ST policy in 2010. There were 280,271 patients (5,960 ST and 275,927 Other) 
with at least one biologic in the Rx claims, 274,495 with at least one claim in the 
Rx and Px combined data (7,936 ST and 266,559 Other), and 271,635 with claims 
for SC biologics in the Rx data (5,853 ST and 267,379 Other). There was less than a 
4.6% difference in patient market share within any individual products, when 
comparing market shares of products within ST policies vs Other policies. These 
results were consistent for all Rx, Rx and Px, and for the Rx only cohort, 
including when restricted to only SC products. CONCLUSIONS: Policies designed 
to reduce overall patient proportions using infusion biologics suggest only a very 
modest effect in this population-level comparison.  
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OBJECTIVES: To evaluate the pattern of opioid analgesic use among children in 
the US using two large databases which are representative of the US 
Commercially insured and Medicaid populations. METHODS: A retrospective 
claims database study was conducted using the MarketScan Commercial 
Database (2006-2010) and the MarketScan Multi-state Medicaid Database  
(2006-2008). We included children 2-17 years of age who had a prescription claim 
for oral opioids excluding cough syrups. Children who had at least one 5-day or 
more supply of opioid prescription claims were included. An opioid length of 
therapy continued until there was a 6-day (or greater) gap to the next opioid 
prescription. A Kaplan-Meier curve was used to display the time to opioid 
discontinuation. RESULTS: Of 1,544,397 children in the Commercial database 
who had 1 or more opioid prescriptions, 488,606 children met all inclusion  
and exclusion criteria. Approximately 49% were girls and the overall mean  
age was 11.4 years. Using the first opioid episode during the 5-year study period, 
the mean length of opioid therapy was 8.2 days (median = 6 days). 91.2% 
(n=445,569) of children discontinued opioids (IR or ER) within 2 weeks. 40.1% 
(n=195,889) were on opioid for 5 days while 51.1% (249,680) of children  
used opioids between 6 and 14 days. The Kaplan-Meier curve shows that  
only 0.07% of children were on opioids for 12 weeks or more. Data from the 
Medicaid database were consistent with the Commercial database results. 
CONCLUSIONS: Ninety percent of children in both Commercial and Medicaid 
populations were prescribed opioids for 5 days to 2 weeks. Only 0.07% and 0.2% 
of children 2-17 years of age in the US Commercial and Medicaid population 
databases had opioid prescription claims for 12 weeks or more. This study shows 
that opioids are rarely used chronically (≥4 weeks) within the US pediatric 
population.  
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OBJECTIVES: The FDA is trying to reduce over-the-counter (OTC) product misuse 
by providing appropriate warnings on the Drug Facts panel. This study assessed 
relationship between consumers’ risk cognition of liver damage associated with 
inappropriate use of OTC acetaminophen products and their intention to 
perform protective behavior. METHODS: A within-subject experimental study 
design was employed to recruit adults visiting selected pharmacy stores in 
Houston. Respondents were randomly exposed to labels containing organ-
specific warnings for OTC acetaminophen products. Risk cognition measures 
(perceived severity, perceived vulnerability, response efficacy, and self-efficacy) 
and intention to perform protective behavior (always read warnings, use with 
more caution, and consult a pharmacist/physician) were recorded using a 7-
point Likert scale where 1=strongly disagree and 7=strongly agree. Spearman 
correlation and multiple linear regression analyses were performed controlling 
for demographics, usage characteristic, and attitude towards the use of OTC 
products, at an a priori significance level of 0.05 using SAS 9.3. RESULTS: A total 
of 200 completed surveys were obtained. Items measuring intention to perform 
protective behavior showed strong internal consistency (Standardized 
Chronbach’s alpha=0.8). Mean intention towards protective behavior (4.9 ± 1.3) 
was positively correlated with risk cognition measures: perceived severity 
(r=0.46288, p<0.0001), perceived vulnerability (r=0.35052, p<.0001), and response 
efficacy (r=0.30650, p<0.0001). Regression analysis indicated that a unit increase 
in perceived severity significantly increased the intention to read the warnings 
carefully (β=0.28092, p<0.0001) and consult a pharmacist/physician (β=0.30071, 
p<0.0001). A unit increase in perceived vulnerability significantly increased the 
intention to be more cautious (β=0.30381, p<0.0001) when using OTC 
acetaminophen products. CONCLUSIONS: Consumers demonstrating higher risk 
cognition of liver damage exhibited greater intention to perform protective 
behavior when using OTC acetaminophen products. Educational interventions 
targeting appropriate use of OTC products as per the Drug Facts panel could 
improve risk cognition, and thus intensify consumer intention to perform 
protective behavior.  
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OBJECTIVES: To examine treatment patterns of ankylosing spondylitis (AS) 
patients who initiated anti-tumor necrosis factor (TNF) and non-TNF biologic 
agents, via a visualization tool. METHODS: Patients with at least one AS 
diagnosis were identified from the Veterans Health Administration (VHA) 
Medical SAS and Medicare claims datasets. Patients identified from the VHA 
were required to be at least 18 years old, and those from Medicare at least 65 
years. AS patients who initiated therapy with anti-TNF and non-TNF biologic 
agents were identified. Switches from an anti-TNF to a non-TNF or vice versa 
within two years after initial treatment were examined. Initial treatment 
continuation and discontinuation rates were also calculated. Switching patterns 
up to two switches were identified using a processing language and illustrated in 
a data visualization tool. RESULTS: In the Medicare sample, 1159 AS patients 
initiated anti-TNF, of which 5.69% switched to another anti-TNF, 55.91% 
discontinued therapy and 35.72% remained on their initial therapy. A total of 532 
AS Medicare patients initiated a non-TNF, of which 1.5% switched to an anti-
TNF, and only 3.95% remained on the initial therapy. In the VHA sample, 1021 AS 
patients initiated therapy with an anti-TNF, of which 13.52% switched to another 
anti-TNF type, 49.56% discontinued therapy and 36.73% remained on their initial 
therapy. A total of 84 AS patients from the VHA initiated non-TNF therapy, of 
which 4.76% switched to an anti-TNF and no patients remained on their initial 
therapy. CONCLUSIONS: Patients who initiated anti-TNF therapy were more 
likely to remain with this therapy. The VHA sample had a higher switching rate 
than the Medicare sample. Data visualization tools can help present these 
complicated treatment flows effectively to researchers with a variety of 
specialties and backgrounds.  
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OBJECTIVES: An orphan drug is a drug developed specifically to treat a rare 
medical condition. It is unclear how well rare-disease patients in the Middle East 
are able to obtain orphan drugs. In this study, we provide a critical review of the 
literature on the availability of orphan drugs in the Middle East. METHODS: 
Using Medline and other internet-based search engines, a critical review of both 
English and Arabic literature and other documents was performed to identify 
and evaluate 1) the prevalence of rare diseases in the Middle East; 2) problems 
with diagnosis of rare diseases in Arab countries; 3) availability of orphan drugs 
in the Middle East; and 4) development by pharmaceutical companies of orphan 
drugs for Arab diseases. RESULTS: Approximately 2.8 million patients are 
estimated to be suffering from a rare disease in the Middle East. Genetic 
disorders such as haemoglobinopathies, glucose-6-phosphate dehydrogenase 
deficiency, and autosomal recessive syndromes have a presence throughout the 
Middle East, with the latter’s occurring in approximately 1 out of 3,500 newborns. 
The prevalence of Behcet disease was estimated to be 2.23, 1.35, and 1.25 per 
100,000 in Bahrain, Kuwait, and Oman, respectively. To help with diagnosis, the 
Centre for Arab Genomic Studies has constructed a rare-disease database. 
Despite the high expense of orphan drugs, some health care companies, such as 
Taiba, currently market and distribute orphan drugs. The Dubai Biotechnology & 
Research Park provides an environment for life sciences companies to work in 
the Middle East. CONCLUSIONS: In order to promote the treatment of rare 
diseases, Middle Eastern governments need to facilitate education and training 
of health care personnel; develop and execute a method for obtaining and paying 
for orphan drugs; and provide tax, marketing, and other incentives to domestic 
and international firms to develop drugs specifically for the diseases of most 
importance to Middle Eastern patients.  
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